cetrorelix

(redirected from Cetrotide)

cetrorelix

 [set″ro-rel´iks]
a gonadotropin-releasing hormone antagonist, used to inhibit premature luteinizing hormone surges in women undergoing controlled ovarian stimulation during infertility treatment; administered subcutaneously.
References in periodicals archive ?
GnRH Antagonist (0.25 mg cetrorelix acetate, Cetrotide, Serono) was added when the diameter of follicle reached 12 mm.
In the study group (delayed start protocol), COS was performed seven days after GnRH antagonist pretreatment with administration of 250 [micro]g Cetrotide per night on cycle day two to seven.
Day 7 (Jan 30) I take my first Cetrotide injection to prevent ovulation (to keep all those growing eggs inside).
The following morning, I take my first Cetrotide injection, to prevent ovulation (to keep all those growing eggs inside).
After continuous injection of FSH, 0.25 mg GnRH antagonist (Cetrotide, Serono, Germany) was injected at the 7th-8th day of the menstrual cycle or the follicle diameter was >14 mm.
Controlled ovarian hyperstimulation (COH) was initiated on the third day of the menstrual cycle with high dose recombinant FSH (rFSH, Gonal F, Merck Serono, Rome, Italy) and GnRH antagonist (cetrorelix, Cetrotide, Baxter Oncology GmbH, Frankfurt, Germany) to prevent premature ovulation.
Preoperative reduction of uterine fibroids in only 16 days by administration of a gonadotrophin-releasing hormone antagonist (Cetrotide).
The treatment was carried out with GnRH antagonist downregulated protocol using cetrorelix (Cetrotide; Merck Serono, UK).
When the leading follicle reached the size of 14 mm and/or the levels of estradiol reached the value >300 pg/mL, a daily injection of cetrorelix 0.25 mg (Cetrotide; Merc Serono, Switzerland) was included.
GnRH antagonist fixed protocol included direct gonadotropin suppression via the subcutaneous administration of cetrorelix acetate (Cetrotide 0.25mg(R); Merck Serono) 0.25mg/day on 6th day of the menstrual cycle.
aromatase inhibitor, Letrozole 2.5 mg/day (Femara; Novartis, Istanbul, Turkey) then rFSH 150-300 IU/day (Gonal-F; Merck Serono, Istanbul,Turkey) was added to the protocol two to three days later.6 GnRH antagonist (0.25 mg/day Cetrotide; Merck) was used from the 6th day of the stimulation protocol to prevent premature LH surge.